News | Antiplatelet and Anticoagulation Therapies | May 18, 2018

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin

Understanding the real-world performance of systemic anticoagulation in atrial fibrillation

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral anticoagulants do not maintain adherence above 80 percent. This leads to increased risks for thromboembolic events. This was according to a new study presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Anticoagulation (AC) mitigates risk of thromboembolic events (TE) in patients with non-valvular atrial fibrillation (AF or Afib). Warfarin for decades, and recently direct oral anticoagulants (DOACs — a newer term for novel oral anticoagulants, or NOAC) have been effective. Real-world data have pointed to inconsistent adherence to anticoagulation, but it is not clear if event risk is elevated during gaps or if events occur even during periods of adherence.

The cohort included 52,365 patients prescribed warfarin and 67,686 prescribed any of the four DOACs. Lower adherence occurred in 47% of patients using warfarin and 31% on DOACs. Compared to higher-adherence warfarin, thromboembolic events were 14% less likely for higher-adherence DOAC (P<0.001), 48% more likely for lower-adherence warfarin (P<0.001) and 69% more likely for lower-adherence DOAC (P<0.001).

This observational cohort study evaluated administrative claims for patients in the IBM Watson Health Market Scan databases receiving a prescription of warfarin or a DOAC for anticoagulation for nonvalvular atrial fibrillation (NVAF) from  2015 to 2016. Exclusions were CHA2 DS2-VASc 0-1, transient AF, other requirement for AC, thrombocytopenia and anemia. The remaining patients were stratified based on index prescription (warfarin or DOAC). Outcomes, through December 2016, were hospitalization for TE (ischemic stroke or systemic embolism), hemorrhagic stroke or major bleeding. Event rates are reported for warfarin and DOACs at higher adherence (dosage covering >80% of days) and lower adherence (covering 40-80% of days). A Cox proportional-hazards model will incorporate basic characteristics, comorbidities and a time-dependent covariate for anticoagulation based on prescription dosage to associate adherence to outcomes.

Researchers said they plan to update the abstract with 2017 data and use the time-dependent Cox model to determine if event risk is higher during medication usage or gaps in adherence. Patients with lower adherence may be candidates for device therapies that obviate the need for chronic AC.

The study was presented by Dhanunjaya R. Lakkireddy, M.D., FHRS, from Kansas City Heart Rhythm Institute in Overland Park, Kansas.

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

#HRS2018 #HRS18

Related Content

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Overlay Init